Aileron initiates patient treatment in first clinical Ph1b/2 trial of ALRN-6924
Aileron Therapeutics announced the first patient has completed the initial cycle of treatment in the Company’s first clinical trial evaluating ALRN-6924 as a myelopreservation agent in patients with p53-mutant small-cell lung cancers treated with the chemotherapy topotecan. October 16, 2019